Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Switzerland / NCT05182892
Recruiting Not applicable

REducing SPEECH-related Side-effects of Deep Brain Stimulation in Parkinson's Disease Via Automated Speech Analysis

NCT05182892 · tracked via the Priya Life Science Switzerland tracker
Phase
Not applicable
Started
2021-12-13
Last updated
2025-04-09

Condition(s) studied

Parkinson Disease

Investigational drug(s) / intervention(s)

Change of stimulation amplitudes in dopaminergic OFF drug state

Change of stimulation amplitudes in dopaminergic OFF drug state: Change of stimulation amplitudes during experiment in dopaminergic OFF drug state.

Study summary

The investigators' objective is to improve L-dopa sensitive PD-related dysarthria and at the same time reduce DBS-induced speech disorders with the help of automated acoustic analysis in patients with STN-DBS-induced dysarthria.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Idiopathic Parkinson-Syndrome according to the Movement Disorders Society Criteria * Treatment with bilateral deep brain stimulation in the subthalamic nucleus (for parts 1, 2 and 3) * Time since DBS-STN operation ≥ 3 month (for parts 1, 2 and 3) * Able to give informed consent as documented by signature * Fluent in Swiss-German or German * STN-DBS-induced dysarthria. In an operational definition, all PD-patients who reported -worsening of speech time-locked to STN-DBS implantation or patients with dysarthria on chronic stimulation improving with reduction of stimulation amplitudes in the context of postoperative routine follow up will be defined as having STN-DBS-induced dysarthria Exclusion Criteria: * Dysarthria caused in addition by a condition other than PD or DBS (e.g. stroke, myasthenia) * Clinical diagnosis of aphasia * Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders and dementia. A Montreal Cognitive Assesment (MoCa) will be performed and patients with ≤ 20 of 30 points will be excluded * Change of parkinsonian medication in the last four weeks prior to inclusion in part 1 and 3 * Change of STN-DBS parameters in the last four weeks prior to inclusion (for parts 1 and 3) * Depression with acute suicidal ideation * Pregnant women

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Czech Technical University Prague Prague Czechia Active Not Recruiting
University Hospital Inselspital, Berne Bern Switzerland Recruiting

More Insel Gruppe AG, University Hospital Bern trials in Switzerland

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05182892 on ClinicalTrials.gov ↗ ← All trials in Switzerland